Alfred Clinical Trials

Alfred Health has more than 700 open trials across 20 clinical disciplines, our clinical trial portfolio is one of the largest in the country.

Clear filter
604 clinical trials found
Clinical trials

ASPIRE-AF

Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial (NCT03968393)

Currently recruiting

APG2575AU101

APG2575AU101 A Phase Ib/II Study of APG-2575 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS) (NCT04964518)

Currently recruiting

ARTEMIS

ARTEMIS- Effects of Ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction (105277)

Currently recruiting

ASCEND

ASCEND - A Randomised, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma (NCT05042128)

No longer recruiting

PTeye

Assessing Benefits of Near Infrared Autofluorescence Detection for Identifying Parathyroid Glands during Endocrine Surgery (NCT05022667)

Currently recruiting

SuperQoL

Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy and symptom control, on quality of life in patients with pancreatic cancer: a randomised control trial. (ACTRN12624000084583)

Currently recruiting

DRESS

Assessing the role of mepolizumab in DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome: a pilot study (ACTRN12621001333808)

Recently completed/closed

AMEND-CRT

Assessment of MEchaNical Dyssynchrony versus standard selection on clinical response in candidates for Cardiac Resynchronization Therapy – The AMEND-CRT Trial (NCT04225520)

Currently recruiting

TRAILBLAZER-ALZ 2

Assessment of Safety, Tolerability, and Efficacy of LY3002813 in Early Symptomatic Alzheimer’s Disease (NCT04437511)

Currently recruiting

ARISE_FLUIDS

Australasian Resuscitation In Sepsis Evaluation: FLUid or vasopressors In emergency Department Sepsis (NCT04569942)

Recently completed/closed

ACEMID

Australian Centre of Excellence in Melanoma Imaging & Diagnosis (ACEMID) Cohort Study (ACTRN12619001706167)

Currently recruiting

Ava NEXT

Avatrombopag in Relapsed or Refractory severe Aplastic Anaemia as EXtra Therapy - Ava NEXT– a Bayesian Optimal Phase II study (ACTRN12619001043123)

Currently recruiting

Ava FIRST

Avatrombopag plus up Front ImmunosuppReSsive Therapy in treatment-naive severe aplastic anaemia (AA) – Ava FIRST- a Bayesian Optimal Phase II study (ACTRN12619001042134)

Currently recruiting

Baz in Men with Scz

Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for Men with Schizophrenia: a double-blind, randomized, placebo-controlled trial (ACTRN12619001471178p)

Currently recruiting

Baz in Women with Scz

Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for Women with Schizophrenia: a double-blind, randomized, placebo controlled trial (NCT04113993)

Currently recruiting

BLENDER

Bend to Limit oxygEN in ECMO: a ranDomised controllEd Registry trial. (NCT03841084)

Recently completed/closed

BETTER

Bevacizumab and immune chEckpoint inhibitors plus hypofractionated stereotactic radioTherapy for the treatment of sympTomatic mElanoma bRain metastases (NCT06163820)

Currently recruiting

BGB-11417-303

BGB-11417-303 A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT06943872)

Currently recruiting

BHV3000-406

BHV3000-406: A Phase 4, Randomized, Doubleblind Placebo-Controlled, Efficacy and TolerabilityTrial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use (NCT05509400)

Currently recruiting

CorSky

BIO|CONCEPT.CorSky Family (NCT05610176)

Currently recruiting
18 19 20 21 22